- PR Newswire•1 hour agoArena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial. Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). "This marks an important step in the development of ralinepag and is evidence of our strategic focus on our pipeline," said Amit Munshi, Arena's President and CEO. Pulmonary arterial hypertension (PAH) is a rare, progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs.
- PR Newswire•7 days agoArena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference
SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & ...
ARNA : Summary for Arena Pharmaceuticals, Inc. - Yahoo Finance
Arena Pharmaceuticals, Inc. (ARNA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||1.43 x 1000|
|Ask||1.50 x 600|
|Day's Range||1.42 - 1.48|
|52 Week Range||1.30 - 2.16|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|